Emyria Executive Chair to Lead Mental Health Innovation Panel at Sydney Impact Investment Summit on August 6, 2026

Emyria's Comprehensive Clinical Services and Treatment Development Model

Emyria Limited operates an integrated business model combining direct clinical services with treatment development for patients suffering from mental health and select neurological conditions. Through Emyria Healthcare, the company provides evidence-based treatments for patients unresponsive to conventional care. This clinical division also serves as a platform to evaluate emerging therapies such as assisted treatments for post-traumatic stress disorder (PTSD) and treatment-resistant depression. This direct patient care approach enables Emyria to collect real-world clinical evidence while delivering immediate therapeutic benefits.

Emyria Data, a separate division, focuses on collecting robust and ethically sourced real-world data directly from patients. This data informs and enhances Emyria's unique therapy methods and drug development programs. The company’s Pipeline includes new psychedelic-assisted therapies and drug treatments targeting mental health and select neurological diseases. This threefold structure—clinical healthcare delivery, real-world data collection, and treatment pipeline development—positions Emyria to create clinically relevant therapeutics grounded in patient experience and current evidence.

Greg Hutchinson to Participate in Mental Healthcare Innovation Panel

Executive Chair Greg Hutchinson will join a panel exploring diverse mental healthcare delivery approaches. The discussion will address preventative mental health programs, digital mental health solutions, and emerging treatment pathways aimed at expanding access to evidence-based care. This involvement highlights Emyria's role in contributing to industry-wide efforts to tackle the mental health crisis through multiple care modalities. It also signals the company's readiness to engage beyond its clinical operations.

Hutchinson’s participation reflects his leadership in bridging clinical care delivery with emerging therapeutic development. The panel format facilitates comparative discussions of mental healthcare models and allows Emyria to share its expertise in intensive mental health treatment alongside other sector leaders. The invitation affirms the value placed on Emyria’s integrated clinical and treatment innovation approach by industry conveners and impact investors.

Event Details: Addressing the Mental Health Crisis Summit

The "Addressing the Mental Health Crisis" event is hosted by Impact Investment Summit and Novar Impact Capital, organizations dedicated to uniting mental health sector leaders to discuss the latest treatment innovations. Scheduled for Thursday, 6 August 2026, from 5:30PM to 8PM AEST at Esther Lane, Surry Hills, Sydney, the venue’s central location is expected to attract mental health professionals, investors, policymakers, and stakeholders interested in innovative care delivery.

The event’s focus on addressing the mental health crisis reflects ongoing challenges with treatment gaps and unmet patient needs. By bringing together diverse sector leaders, it fosters cross-sector dialogue on emerging care models and treatment pathways. Emyria’s participation demonstrates its commitment to sharing clinical expertise and treatment development insights to scale mental health solutions.

Emerging Role of Psychedelic-Assisted Therapies in Mental Health Treatment

The panel will examine the role of psychedelic-assisted therapies within evidence-based mental healthcare and their potential to meet unmet patient needs. These therapies combine pharmaceutical agents with structured psychological support and represent a growing class of innovative treatments. Discussions will explore expanding access for patients with PTSD and treatment-resistant depression who do not respond adequately to conventional therapies, reflecting increasing research interest in psychedelic compounds as therapeutic agents in controlled clinical settings.

Emyria’s inclusion in these discussions highlights its active development of psychedelic-assisted therapies and drug treatments within its pipeline. The event offers a platform to communicate Emyria’s rigorous clinical evaluation, controlled therapeutic administration, and patient-centered outcome measurement approaches in psychedelic-assisted care. This aligns with broader industry recognition that conventional treatments may not suffice for all patient groups.

Industry Recognition of Emyria's Leadership in Evidence-Based Mental Healthcare

Emyria’s invitation to present at this leading industry event underscores its growing reputation as a provider of evidence-based intensive mental health care. The company’s integrated clinical and research model combines patient care with rigorous data collection and treatment development. This dual-track approach—addressing current patient needs while innovating next-generation treatments—distinguishes Emyria from traditional healthcare providers and pharmaceutical developers. Impact Investment Summit and Novar Impact Capital specifically acknowledge this integrated mental healthcare delivery and innovation approach.

Executive Chair Greg Hutchinson emphasized in the company update that addressing Australia’s mental health challenges requires "a broad range of evidence-based approaches." This philosophy acknowledges that no single treatment suits all patients and that expanding mental health access involves multiple pathways including intensive in-person care, digital solutions, preventative strategies, and emerging therapies. Emyria’s engagement in cross-sector discussions positions it as a collaborative leader tackling complex healthcare challenges at scale.

Focus on Preventative Mental Health and Digital Solutions

The event agenda includes preventative mental health initiatives alongside established treatment pathways. Preventative approaches aim to identify and support individuals before severe conditions develop, reducing disease burden and improving population mental health. Digital mental health solutions expand care access via technology platforms, reaching patients beyond geographic and clinic limitations. These discussions contextualize Emyria’s work within a broader mental health innovation ecosystem spanning multiple delivery methods and intervention points.

Emyria’s participation across preventative care, digital solutions, and intensive clinical treatment discussions demonstrates recognition of their complementary roles in addressing mental health crises. While primarily focused on intensive evidence-based clinical care and psychedelic-assisted therapies, Emyria shows willingness to explore its place within a comprehensive mental health framework. This systems-level perspective appeals to investors and stakeholders seeking holistic mental health solutions rather than isolated interventions.

Real-World Data Collection and Clinical Evidence Generation at Emyria

Emyria Data is a core differentiator, generating robust, ethically sourced real-world data collected directly from patients during clinical treatment. This framework creates a feedback loop where patient outcomes inform therapy improvements and drug development. Unlike clinical trial data, real-world data captures patient experiences in actual clinical settings, reflecting diverse populations and complexities. This approach enables development of therapies grounded in contemporary clinical practice rather than isolated research environments.

Emyria’s commitment to ethical data collection respects patient interests and fosters trust through transparent, consent-based processes. This data-driven approach to therapy development resonates with investors and healthcare leaders focused on evidence-based medicine and patient-centered outcomes. Industry discussions offer Emyria opportunities to highlight advantages of its integrated clinical and data collection model over traditional pharmaceutical or healthcare service models.

Mental Health Crisis as a Growth Catalyst for Emyria

Mental health remains a critical healthcare challenge in Australia, driving demand for effective new treatments. Conventional therapies often fail significant patient groups, leaving many with treatment-resistant conditions. This unmet need creates opportunities for companies like Emyria that develop evidence-based intensive care and innovative therapeutic pathways. The mental health crisis is both a humanitarian issue and a business driver for companies addressing treatment gaps.

Emyria’s event invitation reflects its position to capitalize on growing recognition that innovative mental health solutions are essential. With rising mental health prevalence, persistent treatment resistance, and expanding digital health capacities, Emyria’s integrated clinical and development model is well placed to meet increasing demand. Participation in high-level industry forums reinforces its role as a key player in this evolving sector.

Forward-Looking Clinical Development and Regulatory Considerations

The update notes event discussions will explore emerging treatment models, especially psychedelic-assisted therapies. These approaches require rigorous clinical development and regulatory approvals before broad availability. The announcement includes cautionary statements about risks associated with MDMA, MDMA-inspired compounds, and psilocybin, reflecting regulatory and clinical complexities. Emyria makes no claims regarding safety or efficacy or the ability to treat conditions like PTSD without clinical trial data and regulatory clearance.

The regulatory landscape for psychedelic-assisted therapies is evolving in Australia and globally. The Therapeutic Goods Administration (TGA) has not approved MDMA, psilocybin, or related compounds for therapeutic use. Emyria’s development efforts must navigate complex regulatory pathways that may take significant time. Participation in industry discussions reflects both opportunity and uncertainty about commercial viability and regulatory status. Investors should monitor regulatory developments and clinical outcomes closely.

Safety and Risk Profile of Psychedelic-Assisted Therapies

The company update details adverse effects and safety considerations for MDMA, MDMA-inspired compounds, and psilocybin. MDMA’s side effects include elevated blood pressure, increased heart rate, faintness, panic attacks, and rarely loss of consciousness or seizures, plus symptoms like jaw clenching, decreased appetite, restless legs, nausea, headache, sweating, and muscle stiffness. Psilocybin may cause temporary blood pressure and heart rate increases and carries psychosis risk in predisposed individuals. The risk profile of MDMA-inspired compounds remains unknown. These risks highlight the medical complexity of developing and administering psychedelic-assisted therapies.

Emyria emphasizes that low doses used in psychedelic-assisted psychotherapy, administered in controlled clinical settings with medical supervision, are unlikely to produce these effects. This therapeutic model involves integrated clinical protocols with psychiatric oversight and psychological support. The risk considerations underscore that psychedelic-assisted therapies are complex clinical interventions, not simple pharmaceuticals. Successful commercialization requires demonstration of safety and efficacy through rigorous trials and regulatory approvals, which may take years.